CXCL1 in Noncancer Diseases of the Cardiovascular System: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Sirius Huang and Version 1 by Irena Baranowska-Bosiacka.

CXC motif chemokine ligand 1 (CXCL1), a cytokine belonging to the CXC sub-family of chemokines with CXC motif chemokine receptor 2 (CXCR2) as its main receptor, causes the migration and infiltration of neutrophils to the sites of high expression. This implicates CXCL1 in many adverse conditions associated with inflammation and the accumulation of neutrophils. Herein, the significance of CXCL1 in selected diseases of the cardiovascular system is described.

  • CXCL1
  • CXCR2
  • atherosclerosis
  • cardiovascular system

1. The Physiology of Blood Vessels

CXCL1 is important in blood vessel function due to its pro-angiogenic properties–promoting the CXCR2-dependent proliferation, migration and tube formation of endothelial cells [31,32][1][2]. CXCL1 expression is upregulated by vascular endothelial growth factor (VEGF) [33,34][3][4]. Therefore, VEGF and CXCL1 factors participate together in angiogenesis. The described influence of CXCL1 on endothelial cells also implicates CXCL1 in blood vessel regeneration as CXCL1 expression in endothelial cells is increased by tissue factor, the primary initiator of blood coagulation [35][5]. CXCL1 also causes the recruitment of circulating endothelial progenitor cells [36[6][7],37], endothelial cell chemotaxis and proliferation [31[1][2][8],32,38], processes that lead to wound repair.
At the same time, CXCL1 in blood vessels can also cause disease complications. In particular, angioplasty and stenting can lead to neointima formation and to the re-stenosis of blood vessels [39][9]. This process is dependent on the production of CC motif chemokine ligand 2 (CCL2) and CXCL1 by smooth muscle cells. These chemokines induce the recruitment of Sca-1+ vascular stem/progenitor cells to blood vessel sites that have undergone angioplasty and stenting, in processes dependent on CXCR2 and CC motif chemokine receptor 2 (CCR2). The recruited Sca-1+ vascular stem/progenitor cells participate in neointima formation [39][9].
CXCL1 is also important in arteriogenesis, as its expression in vein and aortic endothelial cells is increased during increased blood pressure and thus shear stress [40,41][10][11]. This is followed by CXCR2-dependent adhesion of monocytes to endothelial cells [41][11]. These monocytes differentiate into M2 macrophages [42][12] which then secrete growth factors that act on smooth muscle cells and endothelial cells, thus enabling collateral remodeling and arteriogenesis [43][13].

2. Atherosclerosis

Atherosclerosis is an arterial disease that is characterized by inflammatory reactions in the blood vessel walls, intimal lipoprotein deposition and the formation of atherosclerotic plaques in advanced stages of the disease [44][14]. Atherosclerosis leads to atherosclerotic cardiovascular disease (CVD) which often ends in death due to myocardial infarction or ischemic stroke (it is estimated that 31% of all deaths worldwide are related to CVD) [45][15]. In this disease, the development of atherosclerosis involves macrophages. These cells, under the influence of oxidized low-density lipoprotein (oxLDL), are converted to foam cells.
CXCL1 is another element in the pathophysiology of atherosclerosis. Expression of this chemokine and CXCR2 receptor occurs in humans in the intima of atherosclerotic lesions [46][16]. oxLDL causes an increase in CXCR2 expression on peripheral blood monocytes [47][17]. Activated mast cells [48][18] and macrophages, in particular those interacting with vascular smooth muscle cells [49][19], produce CXCL1 in intima and perivascular tissue. Another source of CXCL1 in arterial vessel walls is endothelial cells where oxLDL increases the expression of CXCL1 [50][20]. At the same time, lysophosphatidic acid (LPA) may also be responsible for the production of CXCR2 ligands in arterial vessel walls [51][21]. LPA induces an increase in the release of endothelial CXCL1, or at least CXCL1/KC, the murine paralog for human CXCL1, as shown by experiments on mice [49][19]. Pro-inflammatory cytokines such as IL-1β and TNF-α are also important factors that increase CXCL1 expression in the inflamed endothelium and atherosclerotic lesions [52][22].
CXCL1 causes the recruitment of neutrophils into the atherosclerotic plaque [48][18]. These cells play an important role in atherosclerotic lesions as the recruited neutrophils secrete pro-inflammatory cytokines that participate in inflammatory responses [53][23]. Neutrophils also secrete proteases which cause plaque destabilization. CXCL1 also affects monocytes. The CXCL1→CXCR2 axis increases adhesion and arrest of monocytes to the inflamed endothelium, which leads to the recruitment of these cells to the vessel wall [46,50,51,54,55][16][20][21][24][25]. The action of CXCL1 in recruiting monocytes to early atherosclerotic lesions seems to be more important than that of CCL2 [54,55][24][25]. However, there are also studies contradicting this and showing that the aforementioned axis is only important in advanced atheromatous plaques [56][26]. CXCL1 also affects monocytes after recruitment. It increases the expression of class A scavenger receptor (SR-A) and cluster of differentiation 36 (CD36) in macrophages [52][22], both being receptors for oxLDL [57,58][27][28]. As CXCL1 increases the accumulation of oxLDL in macrophages, it increases the rate of conversion of these cells to foam cells [52][22].
CXCL1 also causes the release of matrix metalloproteinases (MMPs) from vascular smooth muscle cells, which leads to plaque destabilization (Figure 1) [52][22].
Figure 1. Importance of CXCL1 in atherosclerosis. In atherosclerotic plaque, endothelial cells, macrophages and activated mast cells are responsible for CXCL1 production. This chemokine causes the recruitment of neutrophils and monocytes to atherosclerotic plaque. The effect on monocytes is enhanced by oxLDL, which increases CXCR2 expression on these cells. After recruitment, neutrophils secrete pro-inflammatory cytokines that increase inflammation in the atherosclerotic plaque. These cells also secrete proteases that cause plaque destabilization. In turn, monocytes differentiate into macrophages which, under CXCL1, increase the expression of CD36 and SR-A, receptors for oxLDL. Therefore, CXCL1 increases the uptake of oxLDL by macrophages. This elevates the rate of foam cell formation in the atherosclerotic plaque. Additionally, CXCL1 causes an increase in the production and secretion of MMPs in vascular smooth muscle cells; these are proteases that cause plaque destabilization. Abbreviations: CXCL1–CXC motif chemokine ligand 1; CXCR2–CXC motif chemokine receptor 2; MMP–matrix metalloproteinases; oxLDL–oxidized low-density lipoprotein; SR-A–class A scavenger receptor.
Finally, CXCL1 may also participate in atherosclerosis regression [59][29]. It is responsible for the recruitment of bone-marrow endothelial progenitor cells to atherosclerotic plaque, which leads to plaque resolution.

3. Atrial Fibrillation

One of the consequences of hypertension is atrial fibrillation [60][30]. Patients with atrial fibrillation have higher levels of CXCL1 and CXCR2+ monocytes in their blood [61][31]. At the same time, atrial fibrillation patients have lower CXCL1 expression in the atrium heart tissue and higher CXCR2 expression compared to healthy subjects [62][32]. This suggests that if CXCR2 has a role in the pathogenesis of atrial fibrillation, then it is activated by a ligand other than CXCL1. Animal studies have shown that atrial fibrillation is associated with increased expression of CXCR2 ligands in the atrium and subsequent infiltration by CXCR2+ immune cells [61][31]. In particular, infiltration of monocytes in the atrium tissue leads to an increase in the number of macrophages in the atrium [61][31]. The level of CXCL1 expression in the atrium in patients with atrial fibrillation is strongly positively correlated with activated mast cells, weakly positively correlated with M2 macrophages and negatively correlated with M1 macrophages [63][33]. Mast cells may contribute to atrial fibrillation by secreting platelet-derived growth factor A (PDGF-A) [64][34]. This growth factor increases collagen production by cardiac fibroblasts which leads to atrial fibrosis and atrial fibrillation. At the same time, patients with atrial fibrillation do not experience increased infiltration of atrial tissue by mast cells [65][35], which indicates that this mechanism may not be significant in atrial fibrillation. In humans, an important role in atrial fibrillation may be played by CXCL7/pro-platelet basic protein (PPBP), a ligand of CXCR2. Expression of this chemokine in the atrium in patients with atrial fibrillation is positively correlated with infiltration of atrial tissue by neutrophils and monocytes [63][33]. In addition, CXCL7/PPBP and CXCL1 are the hub gene in atrial fibrillation with the highest number of associations [63][33].

4. Chronic Oschemic Heart Disease

Patients with chronic ischemic heart disease have elevated levels of CXCL1 expression in the blood [66][36] and heart [67][37]. In patients with ischemic heart failure, an increase in cardiac CXCL1 expression may be mediated by T helper type 17 (Th17) cells [67][37]. CXCL1 acts as a chemoattractant for bone marrow-derived endothelial precursors [68][38] which participate in vasculogenesis and thus counteract disease progression. Nevertheless, CXCR2-dependent recruitment of immune cells to the heart occurs after infarction [69][39]. The recruited immune cells cause inflammatory reactions that result in further damage to the heart.

5. Heart Failure

Elevated blood levels of CXCL1 have been observed in patients with heart failure [70,71][40][41]. This increase is correlated with the TT genotype of rs33980500 of TRAF3 Interacting Protein 2 (TRAF3IP2) [70][40]. In contrast, no increase in CXCR2 expression has been observed in the hearts of patients with heart failure [72][42]. This shows that elevated levels of CXCL1 in the blood can lead to heart failure as shown by experiments on laboratory animals. In angiotensin II-treated mice, there is an increase in CXCL1/KC expression in the heart [71][41]. It is a mouse CXCR2 ligand often equated with human CXCL1. The increased expression of CXCR2 ligands in the heart leads to the infiltration of the heart by CXCR2+ immune cells, including macrophages, neutrophils, and T cells [61,71][31][41]. The same results were obtained by studying spontaneously hypertensive rats [73,74][43][44]. In the heart, these immune cells cause cardiac hypertrophy, fibrosis, atrial fibrillation and inflammation [61,69,71][31][39][41]. Mast cellsproduce PDGF-A that causes atrial fibrosis [64][34]. In addition, macrophages cause atrial fibrosis [75][45], inflammation in heart tissue and cardiac hypertrophy [76][46]. These incremental changes in the heart inevitably lead to heart failure [77,78][47][48].

6. Hypertension

CXCL1 can also cause hypertension. People with hypertension have higher levels of CXCL1 in their blood than healthy individuals [79][49]. The mechanism of its involvement in the pathogenesis of hypertension has been studied in laboratory animals. In mice treated with angiotensin II, the resulting hypertension is dependent on the CXCL1/KC→CXCR2 axis [80][50]. In this process, increased CXCL1/KC expression in the aorta leads to infiltration of the aorta by cells with a high CXCR2 expression, in particular by macrophages [80,81][50][51]. At the same time, the infiltration by monocytes, from which macrophages are formed, may depend on activated B cells [82][52]. Macrophages have expression of angiotensin type 1 receptor (AT1R) and angiotensin type 2 receptor (AT2R) and for this reason can respond to angiotensin [83,84][53][54]. Among other things, angiotensin II causes an increase in toll-like receptor 4 (TLR4) expression which leads to an increase in pro-inflammatory cytokine production in macrophages, which results in inflammation in blood vessels [84][54]. Additionally, macrophages in the blood vessel wall under the influence of B cells produce transforming growth factor β (TGF-β), which leads to extracellular matrix remodeling, vascular stiffness and consequent hypertension [84][54].
Hypertension can cause hypertensive retinopathy. Patients with hypertensive retinopathy have higher levels of CXCL1 in their blood than patients with hypertension but without hypertensive retinopathy and healthy individuals. Studies on mice have shown that angiotensin II-induced hypertension increases CXCL1/KC expression in the retina [79][49], which increases infiltration of the retina by CXCR2+ immune cells, particularly by neutrophils and macrophages. In the retina, these cells produce ROS which leads to oxidative stress. These cells are involved in inflammation, which, together with ROS production, leads to retinopathy [79][49].

7. Sepsis

Sepsis is an infection with acute organ dysfunction that often results in death [85][55]. It is difficult to attribute to a particular organ because sepsis causes symptoms in multiple organs. In the US alone, there are 300 cases of sepsis per 100,000 people per year. Researchers have included sepsis as a cardiovascular disease due to the importance of circulation in the early stages of the sepsis course. Sepsis is closely associated with the inflammatory response which is associated with elevated blood levels of pro-inflammatory cytokines such as TNF-α, IL-1β and interleukin-6 (IL-6) [86][56]. CXCL1 levels also tend to increase in sepsis patients, with an increase close to statistical significance relative to healthy individuals (p = 0.07) [87][57]. However, in humans with sepsis, the most important CXCR2 ligand is CXCL8/IL-8, whose blood levels are significantly elevated [87][57]. In sepsis, the CXCR2 ligands have two actions. First, they cause mobilization of neutrophils from the bone marrow and infiltration of various organs by these cells. Then, neutrophils contribute to the eradication of bacterial pathogens [88][58] but also contribute to tissue damage resulting in organ dysfunction.
One of the symptoms of the described disease state is sepsis-associated encephalopathy—damage to the nervous tissue. In the brains of individuals who died from sepsis, expression of CXCL1 was significant in two out of three reported cases [89][59], although increased expression of CXCL8/IL-8 was observed in all three cases. Increased production of CXCR2 ligands is also confirmed in animal models [90,91][60][61]. CXCL1 production in the brain in sepsis is carried out by astrocytes [90][60] and microglial cells [92][62], in a process dependent on pro-inflammatory cytokines. Sepsis-associated encephalopathy is caused by the infiltration of the brain by neutrophils, in a process dependent on the expression of CXCR2 on cerebral endothelial cells [93][63]. Activation of this receptor results in the increased expression of P-selectin, vascular cell adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1), which are involved in the rolling and adhesion of leukocytes and the subsequent recruitment of neutrophils to the brain [90][60]. However, the primary driver of endothelial activation may not be the CXCL1→CXCR2 axis but lipopolysaccharide (LPS) and TNF-α [93][63].
Sepsis also causes acute kidney injury (AKI). Studies on mice have shown that CXCL1/KC and CXCL2/macrophage inflammatory protein-2 (MIP-2) expression is increased in the kidney during sepsis [94,95,96][64][65][66]. CXCL1/KC is a hub gene in septic AKI in mice [96][66]. The IL-17–dependent increase in murine CXCL1/KC and CXCL2/MIP-2 expression in the kidney leads to the infiltration of the kidney by neutrophils [95][65] which contribute to kidney damage by secreting proteases, particularly neutrophil elastase [97][67]. This process occurs in patients with sepsis, as patients with renal dysfunction show an increased neutrophil-to-lymphocyte ratio [98][68]. Nevertheless, further studies are required to demonstrate which CXCR2 ligands are involved in this process in humans.
Murine sepsis is associated with the purinergic receptor P2X7 (P2X7)-dependent generation of reactive species and lipid peroxidation in the liver, leading to the apoptosis of liver cells [99][69]. Additionally in the liver, in hepatocytes, there is a P2X7-dependent increase in the expression of CXCL1/KC and CXCL2/MIP-2 as shown by experiments in mice [99,100,101][69][70][71]. This leads to infiltration of the liver by neutrophils which then cause liver injury in a process dependent on apoptotic cells in the liver [101][71]. CXCL1/KC produced by the liver also causes myeloid-derived suppressor cells (MDSC) mobilization which contributes to the control of systemic inflammation—a mechanism that may mitigate the course of sepsis [102][72]. Nevertheless, the involvement of CXCL1 in liver dysfunction requires further investigation.
Sepsis often leads to ileus, associated with TLR4 activation on myocytes in the ileum, a process which leads to an increase in CXCL1/KC expression in mice [103][73]. This chemokine contributes to reduced contraction amplitude in the ileum and consequently to the ileus [104][74]. Further studies on humans are required to demonstrate which CXCR2 ligand plays an important role in this process.

References

  1. Strieter, R.M.; Polverini, P.J.; Kunkel, S.L.; Arenberg, D.A.; Burdick, M.D.; Kasper, J.; Dzuiba, J.; Van Damme, J.; Walz, A.; Marriott, D.; et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 1995, 270, 27348–27357.
  2. Addison, C.L.; Daniel, T.O.; Burdick, M.D.; Liu, H.; Ehlert, J.E.; Xue, Y.Y.; Buechi, L.; Walz, A.; Richmond, A.; Strieter, R.M. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J. Immunol. 2000, 165, 5269–5277.
  3. Karl, E.; Warner, K.; Zeitlin, B.; Kaneko, T.; Wurtzel, L.; Jin, T.; Chang, J.; Wang, S.; Wang, C.Y.; Strieter, R.M.; et al. Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res. 2005, 65, 5063–5069.
  4. Karl, E.; Zhang, Z.; Dong, Z.; Neiva, K.G.; Soengas, M.S.; Koch, A.E.; Polverini, P.J.; Núñez, G.; Nör, J.E. Unidirectional crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic phenotype of endothelial cells. Cell Death Differ. 2007, 14, 1657–1666.
  5. Grosser, M.; Magdolen, V.; Baretton, G.; Luther, T.; Albrecht, S. Gene expression analysis of HUVEC in response to TF-binding. Thromb. Res. 2011, 127, 259–263.
  6. Hristov, M.; Zernecke, A.; Bidzhekov, K.; Liehn, E.A.; Shagdarsuren, E.; Ludwig, A.; Weber, C. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ. Res. 2007, 100, 590–597.
  7. Kanzler, I.; Tuchscheerer, N.; Steffens, G.; Simsekyilmaz, S.; Konschalla, S.; Kroh, A.; Simons, D.; Asare, Y.; Schober, A.; Bucala, R.; et al. Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis. Basic Res. Cardiol. 2013, 108, 310.
  8. Liehn, E.A.; Schober, A.; Weber, C. Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1891–1896.
  9. Yu, B.; Wong, M.M.; Potter, C.M.; Simpson, R.M.; Karamariti, E.; Zhang, Z.; Zeng, L.; Warren, D.; Hu, Y.; Wang, W.; et al. Vascular Stem/Progenitor Cell Migration Induced by Smooth Muscle Cell-Derived Chemokine (C-C Motif) Ligand 2 and Chemokine (C-X-C motif) Ligand 1 Contributes to Neointima Formation. Stem. Cells 2016, 34, 2368–2380.
  10. Hagiwara, H.; Mitsumata, M.; Yamane, T.; Jin, X.; Yoshida, Y. Laminar shear stress-induced GRO mRNA and protein expression in endothelial cells. Circulation 1998, 98, 2584–2590.
  11. Vries, M.H.; Wagenaar, A.; Verbruggen, S.E.; Molin, D.G.; Dijkgraaf, I.; Hackeng, T.H.; Post, M.J. CXCL1 promotes arteriogenesis through enhanced monocyte recruitment into the peri-collateral space. Angiogenesis 2015, 18, 163–171.
  12. Troidl, C.; Jung, G.; Troidl, K.; Hoffmann, J.; Mollmann, H.; Nef, H.; Schaper, W.; Hamm, C.W.; Schmitz-Rixen, T. The temporal and spatial distribution of macrophage subpopulations during arteriogenesis. Curr. Vasc. Pharmacol. 2013, 11, 5–12.
  13. Zhu, H.; Zhang, M.; Liu, Z.; Xing, J.; Moriasi, C.; Dai, X.; Zou, M.H. AMP-Activated Protein Kinase α1 in Macrophages Promotes Collateral Remodeling and Arteriogenesis in Mice In Vivo. Arterioscler. Thromb. Vasc. Biol. 2016, 36, 1868–1878.
  14. Hopkins, P.N. Molecular biology of atherosclerosis. Physiol. Rev. 2013, 93, 1317–1542.
  15. Libby, P.; Buring, J.E.; Badimon, L.; Hansson, G.K.; Deanfield, J.; Bittencourt, M.S.; Tokgözoğlu, L.; Lewis, E.F. Atherosclerosis. Nat. Rev. Dis. Primers. 2019, 5, 56.
  16. Papadopoulou, C.; Corrigall, V.; Taylor, P.R.; Poston, R.N. The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine 2008, 43, 181–186.
  17. Lei, Z.B.; Zhang, Z.; Jing, Q.; Qin, Y.W.; Pei, G.; Cao, B.Z.; Li, X.Y. OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase. Cardiovasc. Res. 2002, 53, 524–532.
  18. Wezel, A.; Lagraauw, H.M.; van der Velden, D.; de Jager, S.C.; Quax, P.H.; Kuiper, J.; Bot, I. Mast cells mediate neutrophil recruitment during atherosclerotic plaque progression. Atherosclerosis 2015, 241, 289–296.
  19. Tucureanu, M.M.; Butoi, E.; Gan, A.M.; Stan, D.; Constantinescu, C.A.; Calin, M.; Simionescu, M.; Manduteanu, I. Amendment of the cytokine profile in macrophages subsequent to their interaction with smooth muscle cells: Differential modulation by fractalkine and resistin. Cytokine 2016, 83, 250–261.
  20. Schwartz, D.; Andalibi, A.; Chaverri-Almada, L.; Berliner, J.A.; Kirchgessner, T.; Fang, Z.T.; Tekamp-Olson, P.; Lusis, A.J.; Gallegos, C.; Fogelman, A.M.; et al. Role of the GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. J. Clin. Investig. 1994, 94, 1968–1973.
  21. Zhou, Z.; Subramanian, P.; Sevilmis, G.; Globke, B.; Soehnlein, O.; Karshovska, E.; Megens, R.; Heyll, K.; Chun, J.; Saulnier-Blache, J.S.; et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab. 2011, 13, 592–600.
  22. Breland, U.M.; Halvorsen, B.; Hol, J.; Øie, E.; Paulsson-Berne, G.; Yndestad, A.; Smith, C.; Otterdal, K.; Hedin, U.; Waehre, T.; et al. A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: Downregulatory effects of statins. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1005–1011.
  23. Hartwig, H.; Silvestre Roig, C.; Daemen, M.; Lutgens, E.; Soehnlein, O. Neutrophils in atherosclerosis. A brief overview. Hamostaseologie 2015, 35, 121–127.
  24. Huo, Y.; Weber, C.; Forlow, S.B.; Sperandio, M.; Thatte, J.; Mack, M.; Jung, S.; Littman, D.R.; Ley, K. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J. Clin. Investig. 2001, 108, 1307–1314.
  25. Smith, D.F.; Galkina, E.; Ley, K.; Huo, Y. GRO family chemokines are specialized for monocyte arrest from flow. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H1976–H1984.
  26. Boisvert, W.A.; Rose, D.M.; Johnson, K.A.; Fuentes, M.E.; Lira, S.A.; Curtiss, L.K.; Terkeltaub, R.A. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am. J. Pathol. 2006, 168, 1385–1395.
  27. Lin, H.C.; Lii, C.K.; Chen, H.C.; Lin, A.H.; Yang, Y.C.; Chen, H.W. Andrographolide Inhibits Oxidized LDL-Induced Cholesterol Accumulation and Foam Cell Formation in Macrophages. Am. J. Chin. Med. 2018, 46, 87–106.
  28. Jay, A.G.; Chen, A.N.; Paz, M.A.; Hung, J.P.; Hamilton, J.A. CD36 binds oxidized low density lipoprotein (LDL) in a mechanism dependent upon fatty acid binding. J. Biol. Chem. 2015, 290, 4590–4603.
  29. Yao, L.; Heuser-Baker, J.; Herlea-Pana, O.; Iida, R.; Wang, Q.; Zou, M.H.; Barlic-Dicen, J. Bone marrow endothelial progenitors augment atherosclerotic plaque regression in a mouse model of plasma lipid lowering. Stem. Cells 2012, 30, 2720–2731.
  30. Blum, S.; Meyre, P.; Aeschbacher, S.; Berger, S.; Auberson, C.; Briel, M.; Osswald, S.; Conen, D. Incidence and predictors of atrial fibrillation progression: A systematic review and meta-analysis. Heart Rhythm. 2019, 16, 502–510.
  31. Zhang, Y.L.; Cao, H.J.; Han, X.; Teng, F.; Chen, C.; Yang, J.; Yan, X.; Li, P.B.; Liu, Y.; Xia, Y.L.; et al. Chemokine Receptor CXCR-2 Initiates Atrial Fibrillation by Triggering Monocyte Mobilization in Mice. Hypertension 2020, 76, 381–392.
  32. Fan, G.; Wei, J. Identification of potential novel biomarkers and therapeutic targets involved in human atrial fibrillation based on bioinformatics analysis. Kardiol. Pol. 2020, 78, 694–702.
  33. Li, S.; Jiang, Z.; Chao, X.; Jiang, C.; Zhong, G. Identification of key immune-related genes and immune infiltration in atrial fibrillation with valvular heart disease based on bioinformatics analysis. J. Thorac. Dis. 2021, 13, 1785–1798.
  34. Liao, C.H.; Akazawa, H.; Tamagawa, M.; Ito, K.; Yasuda, N.; Kudo, Y.; Yamamoto, R.; Ozasa, Y.; Fujimoto, M.; Wang, P.; et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J. Clin. Investig. 2010, 120, 242–253.
  35. Smorodinova, N.; Bláha, M.; Melenovský, V.; Rozsívalová, K.; Přidal, J.; Ďurišová, M.; Pirk, J.; Kautzner, J.; Kučera, T. Analysis of immune cell populations in atrial myocardium of patients with atrial fibrillation or sinus rhythm. PLoS ONE 2017, 12, e0172691.
  36. Keeley, E.C.; Moorman, J.R.; Liu, L.; Gimple, L.W.; Lipson, L.C.; Ragosta, M.; Taylor, A.M.; Lake, D.E.; Burdick, M.D.; Mehrad, B.; et al. Plasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease. PLoS ONE 2011, 6, e21174.
  37. Chang, S.L.; Hsiao, Y.W.; Tsai, Y.N.; Lin, S.F.; Liu, S.H.; Lin, Y.J.; Lo, L.W.; Chung, F.P.; Chao, T.F.; Hu, Y.F.; et al. Interleukin-17 enhances cardiac ventricular remodeling via activating MAPK pathway in ischemic heart failure. J. Mol. Cell. Cardiol. 2018, 122, 69–79.
  38. Kocher, A.A.; Schuster, M.D.; Bonaros, N.; Lietz, K.; Xiang, G.; Martens, T.P.; Kurlansky, P.A.; Sondermeijer, H.; Witkowski, P.; Boyle, A.; et al. Myocardial homing and neovascularization by human bone marrow angioblasts is regulated by IL-8/Gro CXC chemokines. J. Mol. Cell. Cardiol. 2006, 40, 455–464.
  39. Tarzami, S.T.; Miao, W.; Mani, K.; Lopez, L.; Factor, S.M.; Berman, J.W.; Kitsis, R.N. Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia-reperfusion injury: Recruitment of potentially damaging neutrophils and direct myocardial protection. Circulation 2003, 108, 2387–2392.
  40. Pordel, S.; Sajedi Khanian, M.; Karimi, M.H.; Nikoo, H.; Doroudchi, M. Plasma CXCL1 levels and TRAF3IP2 variants in patients with myocardial infarction. J. Clin. Lab. Anal. 2018, 32, e22402.
  41. Wang, L.; Zhang, Y.L.; Lin, Q.Y.; Liu, Y.; Guan, X.M.; Ma, X.L.; Cao, H.J.; Liu, Y.; Bai, J.; Xia, Y.L.; et al. CXCL1-CXCR2 axis mediates angiotensin II-induced cardiac hypertrophy and remodelling through regulation of monocyte infiltration. Eur. Heart. J. 2018, 39, 1818–1831.
  42. Damås, J.K.; Eiken, H.G.; Oie, E.; Bjerkeli, V.; Yndestad, A.; Ueland, T.; Tonnessen, T.; Geiran, O.R.; Aass, H.; Simonsen, S.; et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc. Res. 2000, 47, 778–787.
  43. Zhang, Y.L.; Geng, C.; Yang, J.; Fang, J.; Yan, X.; Li, P.B.; Zou, L.X.; Chen, C.; Guo, S.B.; Li, H.H.; et al. Chronic inhibition of chemokine receptor CXCR2 attenuates cardiac remodeling and dysfunction in spontaneously hypertensive rats. Biochim. Biophys. Acta Mol. Basis. Dis. 2019, 1865, 165551.
  44. Zhang, Y.L.; Teng, F.; Han, X.; Li, P.B.; Yan, X.; Guo, S.B.; Li, H.H. Selective blocking of CXCR2 prevents and reverses atrial fibrillation in spontaneously hypertensive rats. J. Cell. Mol. Med. 2020, 24, 11272–11282.
  45. Falkenham, A.; de Antueno, R.; Rosin, N.; Betsch, D.; Lee, T.D.; Duncan, R.; Légaré, J.F. Nonclassical resident macrophages are important determinants in the development of myocardial fibrosis. Am. J. Pathol. 2015, 185, 927–942.
  46. Heymans, S.; Corsten, M.F.; Verhesen, W.; Carai, P.; van Leeuwen, R.E.; Custers, K.; Peters, T.; Hazebroek, M.; Stöger, L.; Wijnands, E.; et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 2013, 128, 1420–1432.
  47. Zhang, Y.; Bauersachs, J.; Langer, H.F. Immune mechanisms in heart failure. Eur. J. Heart Fail. 2017, 19, 1379–1389.
  48. González, A.; Schelbert, E.B.; Díez, J.; Butler, J. Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. J. Am. Coll. Cardiol. 2018, 71, 1696–1706.
  49. Wang, S.; Bai, J.; Zhang, Y.L.; Lin, Q.Y.; Han, X.; Qu, W.K.; Zhang, P.F.; Ge, Y.S.; Zhao, Q.; Li, H.H. CXCL1-CXCR2 signalling mediates hypertensive retinopathy by inducing macrophage infiltration. Redox Biol. 2022, 56, 102438.
  50. Wang, L.; Zhao, X.C.; Cui, W.; Ma, Y.Q.; Ren, H.L.; Zhou, X.; Fassett, J.; Yang, Y.Z.; Chen, Y.; Xia, Y.L.; et al. Genetic and Pharmacologic Inhibition of the Chemokine Receptor CXCR2 Prevents Experimental Hypertension and Vascular Dysfunction. Circulation 2016, 134, 1353–1368.
  51. Wenzel, P.; Knorr, M.; Kossmann, S.; Stratmann, J.; Hausding, M.; Schuhmacher, S.; Karbach, S.H.; Schwenk, M.; Yogev, N.; Schulz, E.; et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 2011, 124, 1370–1381.
  52. Chan, C.T.; Sobey, C.G.; Lieu, M.; Ferens, D.; Kett, M.M.; Diep, H.; Kim, H.A.; Krishnan, S.M.; Lewis, C.V.; Salimova, E.; et al. Obligatory Role for B Cells in the Development of Angiotensin II-Dependent Hypertension. Hypertension 2015, 66, 1023–1033.
  53. Okamura, A.; Rakugi, H.; Ohishi, M.; Yanagitani, Y.; Takiuchi, S.; Moriguchi, K.; Fennessy, P.A.; Higaki, J.; Ogihara, T. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J. Hypertens. 1999, 17, 537–545.
  54. Zhang, R.M.; McNerney, K.P.; Riek, A.E.; Bernal-Mizrachi, C. Immunity and Hypertension. Acta Physiol. (Oxf) 2021, 231, e13487.
  55. Cecconi, M.; Evans, L.; Levy, M.; Rhodes, A. Sepsis and septic shock. Lancet 2018, 392, 75–87.
  56. Gille-Johnson, P.; Smedman, C.; Gudmundsdotter, L.; Somell, A.; Nihlmark, K.; Paulie, S.; Andersson, J.; Gårdlund, B. Circulating monocytes are not the major source of plasma cytokines in patients with sepsis. Shock 2012, 38, 577–583.
  57. Cummings, C.J.; Martin, T.R.; Frevert, C.W.; Quan, J.M.; Wong, V.A.; Mongovin, S.M.; Hagen, T.R.; Steinberg, K.P.; Goodman, R.B. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. J. Immunol. 1999, 162, 2341–2346.
  58. Craciun, F.L.; Schuller, E.R.; Remick, D.G. Early enhanced local neutrophil recruitment in peritonitis-induced sepsis improves bacterial clearance and survival. J. Immunol. 2010, 185, 6930–6938.
  59. Warford, J.; Lamport, A.C.; Kennedy, B.; Easton, A.S. Human Brain Chemokine and Cytokine Expression in Sepsis: A Report of Three Cases. Can. J. Neurol. Sci. 2017, 44, 96–104.
  60. Wu, F.; Zhao, Y.; Jiao, T.; Shi, D.; Zhu, X.; Zhang, M.; Shi, M.; Zhou, H. CXCR2 is essential for cerebral endothelial activation and leukocyte recruitment during neuroinflammation. J. Neuroinflammation 2015, 12, 98.
  61. Hasegawa-Ishii, S.; Inaba, M.; Shimada, A. Widespread time-dependent changes in tissue cytokine concentrations in brain regions during the acute phase of endotoxemia in mice. Neurotoxicology 2020, 76, 67–74.
  62. Zhou, H.; Andonegui, G.; Wong, C.H.; Kubes, P. Role of endothelial TLR4 for neutrophil recruitment into central nervous system microvessels in systemic inflammation. J. Immunol. 2009, 183, 5244–5250.
  63. Wu, F.; Chen, X.; Zhai, L.; Wang, H.; Sun, M.; Song, C.; Wang, T.; Qian, Z. CXCR2 antagonist attenuates neutrophil transmigration into brain in a murine model of LPS induced neuroinflammation. Biochem. Biophys. Res. Commun. 2020, 529, 839–845.
  64. Luo, C.J.; Zhang, F.J.; Zhang, L.; Geng, Y.Q.; Li, Q.G.; Hong, Q.; Fu, B.; Zhu, F.; Cui, S.Y.; Feng, Z.; et al. Mesenchymal stem cells ameliorate sepsis-associated acute kidney injury in mice. Shock 2014, 41, 123–129.
  65. Luo, C.J.; Luo, F.; Zhang, L.; Xu, Y.; Cai, G.Y.; Fu, B.; Feng, Z.; Sun, X.F.; Chen, X.M. Knockout of interleukin-17A protects against sepsis-associated acute kidney injury. Ann. Intensive Care 2016, 6, 56.
  66. Liu, B.; Ao, S.; Tan, F.; Ma, W.; Liu, H.; Liang, H.; Yang, X.; Chi, X. Transcriptomic analysis and laboratory experiments reveal potential critical genes and regulatory mechanisms in sepsis-associated acute kidney injury. Ann. Transl. Med. 2022, 10, 737.
  67. Li, G.; Jia, J.; Ji, K.; Gong, X.; Wang, R.; Zhang, X.; Wang, H.; Zang, B. The neutrophil elastase inhibitor, sivelestat, attenuates sepsis-related kidney injury in rats. Int. J. Mol. Med. 2016, 38, 767–775.
  68. Bu, X.; Zhang, L.; Chen, P.; Wu, X. Relation of neutrophil-to-lymphocyte ratio to acute kidney injury in patients with sepsis and septic shock: A retrospective study. Int. Immunopharmacol. 2019, 70, 372–377.
  69. Larrouyet-Sarto, M.L.; Tamura, A.S.; Alves, V.S.; Santana, P.T.; Ciarlini-Magalhães, R.; Rangel, T.P.; Siebert, C.; Hartwig, J.R.; Dos Santos, T.M.; Wyse, A.T.S.; et al. P2X7 receptor deletion attenuates oxidative stress and liver damage in sepsis. Purinergic Signal. 2020, 16, 561–572.
  70. Li, X.; Klintman, D.; Liu, Q.; Sato, T.; Jeppsson, B.; Thorlacius, H. Critical role of CXC chemokines in endotoxemic liver injury in mice. J. Leukoc. Biol. 2004, 75, 443–452.
  71. Dorman, R.B.; Gujral, J.S.; Bajt, M.L.; Farhood, A.; Jaeschke, H. Generation and functional significance of CXC chemokines for neutrophil-induced liver injury during endotoxemia. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288, G880–G886.
  72. Sander, L.E.; Sackett, S.D.; Dierssen, U.; Beraza, N.; Linke, R.P.; Müller, M.; Blander, J.M.; Tacke, F.; Trautwein, C. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J. Exp. Med. 2010, 207, 1453–1464.
  73. Buchholz, B.M.; Shapiro, R.A.; Vodovotz, Y.; Billiar, T.R.; Sodhi, C.P.; Hackam, D.J.; Bauer, A.J. Myocyte TLR4 enhances enteric and systemic inflammation driving late murine endotoxic ileus. Am. J. Physiol. Gastrointest. Liver Physiol. 2015, 308, G852–G862.
  74. Docsa, T.; Bhattarai, D.; Sipos, A.; Wade, C.E.; Cox, C.S., Jr.; Uray, K. CXCL1 is upregulated during the development of ileus resulting in decreased intestinal contractile activity. Neurogastroenterol. Motil. 2020, 32, e13757.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback